The Novo group have announced a commitment to funding early stage development of therapies in the fight against WHO's priority pathogens, which include Enterococcus, Staph and H-pylori infections.
As an industry (and increasingly among the general population) the threat of antibiotic resistance looms large. As the article mentioned, it is estimated than antimicrobial resistance will take more lives than cancers by 2050 - just over three decades' away. Given the time required to develop new treatments, the race is on, and investment like this becomes crucial.
More specifically, the fund will invest in start-ups, early-stage companies and corporate spin-outs, giving priority to first-in-class therapies covering small molecules, biologics and new modalities with investments ranging from $1-$15m. It is also expected that the fund will grow up to $40m per year over the next three to five years from around 20 projects hosted in Europe and the US.